|
8 |
Alteogen Signs License Agreement with AstraZeneca for Subcutaneous Oncology Therapy Development |
Alteogen |
2025-03-17 |
|
7 |
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme Platform |
Alteogen |
2024-11-14 |
|
6 |
Alteogen Announces Amendment to License Agreement with MSD |
Alteogen |
2024-02-22 |
|
5 |
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile |
Alteogen |
2023-09-05 |
|
4 |
Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products |
Alteogen |
2023-01-02 |
|
3 |
Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products |
Alteogen |
2021-01-07 |
|
2 |
Alteogen Enters into a Global License Agreement with a Top Ten Pharmaceutical Company for Use of Its Hybrozyme™ Technology |
Alteogen |
2020-06-24 |
|
1 |
Alteogen Enters Into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of Its Hybrozyme™Technology |
Alteogen |
2019-12-02 |
